PROTEIN X HAS THE POTENTIAL FOR MEDICAL APPLICATION IN HUMAN. IT IS ORIGINALLY FROM A PLANT AND HAD BEEN SUCCESSFULLY CLONED FROM ITS GENE. AFTER MANY ATTEMPTS TO CLONE IT INTO EUKARYOTIC EXPRESSION VECTORS WERE UNSUCCESSFUL, THE RESEARCHER DECIDED TO USE E.COLI EXPRESSION VECTOR. HOW THE RECOMBINANT PROTEIN COULD BE EXPRESSED IN E.COLI EXPRESSION VECTOR. 1. FACTORS AFFECTING BACTERIAL EXPRESSION SYSTEM. 2. STRATEGIES TO IMPROVE THE PROTEIN EXPRESSION. 3. WAYS TO ENSURE THE PROTEIN IS ACTIVELY PRODUCED.

PROTEIN X HAS THE POTENTIAL FOR MEDICAL APPLICATION IN HUMAN. IT IS ORIGINALLY FROM A PLANT AND HAD BEEN SUCCESSFULLY CLONED FROM ITS GENE. AFTER MANY ATTEMPTS TO CLONE IT INTO EUKARYOTIC EXPRESSION VECTORS WERE UNSUCCESSFUL, THE RESEARCHER DECIDED TO USE E.COLI EXPRESSION VECTOR. HOW THE RECOMBINANT PROTEIN COULD BE EXPRESSED IN E.COLI EXPRESSION VECTOR. 1. FACTORS AFFECTING BACTERIAL EXPRESSION SYSTEM. 2. STRATEGIES TO IMPROVE THE PROTEIN EXPRESSION. 3. WAYS TO ENSURE THE PROTEIN IS ACTIVELY PRODUCED.

Name: PROTEIN X HAS THE POTENTIAL FOR MEDICAL APPLICATION IN HUMAN. IT IS OR
Uploaded: 2024-03-20T06:42:41.000Z
Channel: Bartleby
Description: PROTEIN X HAS THE POTENTIAL FOR MEDICAL APPLICATION IN HUMAN. IT IS ORIGINALLY FROM A PLANT AND HAD BEEN SUCCESSFULLY CLONED FROM ITS GENE. AFTER MANY ATTEMPTS TO CLONE IT INTO EUKARYOTIC EXPRESSION VECTORS WERE UNSUCCESSFUL, THE RESEARCHER DECIDED

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter9: Gene Expression And Gene Regulation

Section: Chapter Questions

Problem 10QP: The pre-mRNA transcript and protein made by several mutant genes were examined. The results are...

See similar textbooks

Similar questions

PROTEIN X HAS THE POTENTIAL FOR MEDICAL APPLICATION IN HUMAN. IT IS ORIGINALLY FROM A PLANT AND HAD BEEN SUCCESSFULLY CLONED FROM ITS GENE. AFTER MANY ATTEMPTS TO CLONE IT INTO EUKARYOTIC EXPRESSION VECTORS WERE UNSUCCESSFUL, THE RESEARCHER DECIDED TO USE E.COLI EXPRESSION VECTOR. HOW THE RECOMBINANT PROTEIN COULD BE EXPRESSED IN E.COLI EXPRESSION VECTOR.1. STRATEGIES TO IMPROVE THE PROTEIN EXPRESSION.
PROTEIN X HAS THE POTENTIAL FOR MEDICAL APPLICATION IN HUMAN. IT IS ORIGINALLY FROM A PLANT AND HAD BEEN SUCCESSFULLY CLONED FROM ITS GENE. AFTER MANY ATTEMPTS TO CLONE IT INTO EUKARYOTIC EXPRESSION VECTORS WERE UNSUCCESSFUL, THE RESEARCHER DECIDED TO USE E.COLI EXPRESSION VECTOR. HOW THE RECOMBINANT PROTEIN COULD BE EXPRESSED IN E.COLI EXPRESSION VECTOR.1. FACTORS AFFECTING BACTERIAL EXPRESSION SYSTEM.
You are working for a pharmaceutical company are are tasked with creating E. Coli that express an influenza antigen (a protein that is recognized by our immune system) fortreatment of the influenza virus. The cDNA of the antigen is available in a carrier vector(pCARRY) that contains a kanamycin resistance gene as shown on the left below. Inorder to get E. Coli to express the antigen, you need to clone the gene for the influenzaantigen into an expression vector that contains an E. Coli-specific promoter. You obtain such an expression vector, which contains an ampicillin resistance gene as shown on the right below (pBACTERIA) a. An end generated by digestion with BamH1 can be ligated to an end generated by digestion with BlgII. Why is this possible? b. To clone the gene for the influenza antigen from pCARRY into pBACTERIA plasmid:i. What restriction enzyme should you use to digest pCARRY? ii. What restriction enzyme should you use to digest pBACTERIA? c. After you ligate the products of…
The pre-mRNA transcript and protein made by several mutant genes were examined. The results are given below. Determine where in the gene a likely mutation lies: the promoter region, exon, intron, cap on mRNA, or ribosome binding site. a. normal-length transcript, normal-length nonfunctional protein b. normal-length transcript, no protein made c. normal-length transcript, normal-length mRNA, short nonfunctional protein d. normal-length transcript, longer mRNA, shorter nonfunctional protein e. transcript never made
A full-length eukaryotic gene is inserted into a bacterial chromosome. The gene contains a complete promoter, polyadenylation sequence and a wildtype nucleotide sequence. However, the gene does not produce a functional protein List four reasons why this gene is not expressed in bacteria List five changes you recommend that allow expression of this eukaryotic gene in bacteria
Several research studies are under way that involve the use of genetherapies to inhibit the growth of cancer cells. Oncogenes are mutant genes that are overexpressed and cause cancer. New gene therapies are aimed at silencing oncogenes by producing antisense RNA that recognizes the mRNAtranscribed from oncogenes. Based on your understanding of antisense RNA , explain how this strategy would prevent the growth of cancer cells.
You are working on a protein for a research project. The protein does not express well in prokaryotic expression systems so you decide to try a eukaryotic system, baker’s yeast, instead. As part of the expression system, you add a signal peptide to the protein so that it will be exported through the endomembrane system to the outside of the yeast cell. This makes purifying the protein much simpler. During the purification, you notice that the protein is heavier than it should be during gel filtration chromatography. This is confirmed by SDS-PAGE. What could be the reason that the protein has gained mass when expressed in the eukaryotic system?
Cancer cells were characterized for their high transcriptional and translational levels. Direct modification for the gene of interests during transcription could be complicated and troublesome. Moreover, simply knocked down a certain gene could stimulate other compensating pathways. Fortunately, there are many controls for gene transcription. Modifying on these controls mechanisms could be easier and more effective compared to changing the gene of interests directly. If you are working in a biotech company, please suggest three possible sites/targets to modify in order to decrease a certain gene transcriptional level in cancer cell.
Mass spectrometry is a powerful tool in proteomics. What are the four key features of a mass spectrometer? Describe briefly how MALDI and two-dimensional polyacrylamide gel electrophoresis could be used to identify a protein expressed in cancer cells but not in normal healthy cells.
siRNAs are used to “knockdown” gene expression in research. Imagine you are a scientist who hopes to study several genes related to cancer. Select all the scenarios you will be able to successfully use RNA interference with the use of siRNAs (select all that apply): Group of answer choices Regulate transcript levels by targeting the siRNA to core promoter regions (e.g. TATA box) of tumor suppressor genes Regulate transcript levels by targeting the siRNA to the regulatory promoter regions (e.g. enhancers) of tumor suppressor genes Regulate transcript levels by targeting the siRNA to any region of the processed mRNA Regulate transcript levels by targeting the siRNA to the 5’ UTR of the processed mRNA Regulate transcript levels by targeting the siRNA to the 3’ UTR of the processed mRNA Regulate transcript levels by targeting the siRNA to sites where the histone acetyl transferase will acetylate the histones Regulate transcript levels by targeting the siRNA to where the start…
Describe the difference between a transcriptional fusion and a translational reporter gene fusion. What sequences should you include in each? What types of information can be garnered from their analyses? Please include annotated pictures of the reporter gene expression patterns.
During experimental RNAi, how does the researcher affect expression of a target gene? Group of answer choices Inject custom, lab-made double-stranded RNA into the specimen that will be targeted by the cell's existing Dicer to create siRNA complementary to the target gene's transcript. Inject lab-made Dicer proteins into the specimen which will cut up the target gene's transcript. Inject custom, lab-made siRNAs complementary to the target gene's transcript.